william waddill  calithera biosciences inc  zoominfocom william waddill  calithera biosciences inc  zoominfocom william d waddill calithera cfo elected to protagonist therapeutics board william d waddill calithera cfo elected to protagonist therapeutics board news provided by protagonist therapeutics inc jul    et share this article milpitas calif july   prnewswire  protagonist therapeutics inc today announced the election of william d waddill senior vice president and chief financial officer of calithera biosciences to the protagonist board of directors we are very pleased to welcome will waddill to the board of directors of protagonist said chief executive officer dinesh patel we look forward to benefiting from wills financial leadership and experience within the biotechnology sector as protagonist continues to grow as an organization mr waddill began his career in corporate finance banking and public accounting  years ago prior to joining calithera he was svp and cfo at oncomed pharmaceuticals where he led a successful ipo and private equity financing as well as three significant collaborations prior to that he was svp and cfo at ilypsa where he was finance lead for ilypsas acquisition by amgen before joining ilypsa mr waddill served as the founder and principal at square one finance where he managed the finances of  startup biotechnology companies including eight that became public and six that were acquired he holds a bs in accounting from the university of illinois chicago and certification as a public accountant inactive having begun his career at pricewaterhousecoopers and deloitte in boston about protagonist therapeutics protagonist therapeutics is a clinicalstage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptidebased new chemical entities to address significant unmet medical needs its primary focus is on developing firstinclass oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs compared to injectable antibody drugs protagonists oral peptides offer targeted delivery to the gastrointestinal gi tissue compartment potential for improved safety due to minimal exposure in the blood improved convenience and compliance due to oral delivery lower cost and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease ibd protagonists initial lead product candidates ptg and ptg are based on this approach and the company believes they have the potential to transform the existing treatment paradigm for ibd a gi disease consisting primarily of ulcerative colitis and crohns disease ptg a potential firstinclass oral alphabeta integrin specific antagonist peptide product candidate that is being developed initially for moderatetosevere ulcerative colitis has now completed a phase  clinical trial in normal healthy volunteers  ptg a potential firstinclass oral interleukin receptor antagonist that is being developed initially for moderatetosevere crohns disease is currently in indenabling studies in addition to ptg and ptg the company has several other assets in different stages of research and preclinical development protagonist is headquartered in milpitas california with its preclinical and clinical staff in california and discovery operations both in california and in brisbane queensland australia for further information please visit httpwwwprotagonistinccom logo  httpphotosprnewswirecomprnhmmlogo to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleaseswilliamdwaddillcalitheracfoelectedtoprotagonisttherapeuticsboard9html source protagonist therapeutics inc related links httpwwwprotagonistinccom jul    et preview protagonist therapeutics receives sbir funding for the development of injectable hepcidin mimetics for treatment of iron overload disorders may    et preview protagonist therapeutics to present new data for ptg and ptg at digestive disease week  my news release contains wide tables view fullscreen also from this source jun    et protagonist therapeutics appoints five prime therapeutics ceo may    et protagonist therapeutics enters into worldwide agreement with explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements you just read william d waddill calithera cfo elected to protagonist therapeutics board news provided by protagonist therapeutics inc jul    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft calithera biosciences appoints william d waddill chief financial officer calithera biosciences appoints william d waddill chief financial officer mar    et from calithera biosciences south san francisco calif march   prnewswire  calithera biosciences a clinicalstage biotechnology company focused on the development of novel cancer therapeutics today announced the appointment of william d waddill as senior vice president chief financial officer effective april    as cfo mr waddill will provide input on corporate strategy and oversee all corporate financial matters including financial planning and reporting as well as investor relations  he will report directly to susan molineaux phd president and chief executive officer wills extensive management experience and accomplishments especially in the growth and maturation of life science companies provide calithera with exceptional financial and business leadership said dr molineaux  he brings valuable perspective to our team with firsthand and recent experience contributing to the formation of strategic alliances and guiding companies through diverse fundraising options including an initial public offering  we are privileged to have him join our executive team as our first product candidate advances through phase  clinical studies a life science industry veteran and active member of the biotechnology industry mr waddill joins calithera from oncomed pharmaceuticals where he served as senior vice president cfo since  responsible for all corporate financial matters most notably the successfully completed 9 million initial public offering in july  private equity financing of  million in december  and three collaborations valued at  billion  prior to oncomed mr waddill was senior vice president cfo at ilypsa where he was the finance lead for the  million acquisition by amgen in   before joining ilypsa mr waddill served as the founder and principal at square one finance a financial consulting business managing the finances of  startup biotechnology companies including eight that became public and six that were acquired  mr waddill serves on the board of the association of bioscience financial officers and chaired their  national conference  he also served as the chairman of the biotechnology industry organization bio business solutions advisory board and finance and tax committee  he received a bs in accounting from the university of illinois chicago and certification as a public accountant inactive after working at pricewaterhousecoopers and deloitte in boston this is an exciting time to be joining calithera with lead anticancer compound cb9 progressing in the clinic and having demonstrated promise as a product that may target tumor cell metabolism in hematologic and solid tumor types said mr waddill i look forward to joining susan and her highcaliber team in helping chart the course of the company to support its future success  about calithera biosciences calithera biosciences inc is a clinicalstage company focused on the discovery development and commercialization of firstinclass small molecule oncology therapeutics  the company is building a pipeline of targeted anticancer compounds that inhibit pathways critical to tumor growth and survival  calitheras lead clinical candidate cb9 blocks glutaminase an enzyme critical to tumor metabolism and is currently being tested in patients with advanced solid and hematological cancers  calithera biosciences is headquartered in south san francisco  for more information about calithera biosciences please visit wwwcalitheracom source calithera biosciences related links httpwwwcalitheracom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more apr    et preview calithera biosciences to present data on cb9 at the american association for cancer research annual meeting  mar    et preview calithera biosciences presents preclinical data for cb9 activity and glutaminase inhibition in solid and hematologic tumors my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search william d waddill calithera biosciences inc cfo elected to protagonist therapeutics board employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       william d waddill calithera biosciences inc cala cfo elected to protagonist therapeutics board tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs milpitas calif july   prnewswire  protagonist therapeutics inc today announced the election of william d waddill senior vice president and chief financial officer of calithera biosciences to the protagonist board of directorswe are very pleased to welcome will waddill to the board of directors of protagonist said chief executive officer dinesh patel we look forward to benefiting from wills financial leadership and experience within the biotechnology sector as protagonist continues to grow as an organizationmr waddill began his career in corporate finance banking and public accounting  years ago prior to joining calithera he was svp and cfo at oncomed pharmaceuticals where he led a successful ipo and private equity financing as well as three significant collaborations prior to that he was svp and cfo at ilypsa where he was finance lead for ilypsas acquisition by amgen before joining ilypsa mr waddill served as the founder and principal at square one finance where he managed the finances of  startup biotechnology companies including eight that became public and six that were acquired he holds a bs in accounting from the university of illinois chicago and certification as a public accountant inactive having begun his career at pricewaterhousecoopers and deloitte in bostonabout protagonist therapeuticsprotagonist therapeutics is a clinicalstage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptidebased new chemical entities to address significant unmet medical needs its primary focus is on developing firstinclass oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs compared to injectable antibody drugs protagonists oral peptides offer targeted delivery to the gastrointestinal gi tissue compartment potential for improved safety due to minimal exposure in the blood improved convenience and compliance due to oral delivery lower cost and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease ibd protagonists initial lead product candidates ptg and ptg are based on this approach and the company believes they have the potential to transform the existing treatment paradigm for ibd a gi disease consisting primarily of ulcerative colitis and crohns diseaseptg a potential firstinclass oral alphabeta integrin specific antagonist peptide product candidate that is being developed initially for moderatetosevere ulcerative colitis has now completed a phase  clinical trial in normal healthy volunteers  ptg a potential firstinclass oral interleukin receptor antagonist that is being developed initially for moderatetosevere crohns disease is currently in indenabling studies in addition to ptg and ptg the company has several other assets in different stages of research and preclinical developmentprotagonist is headquartered in milpitas california with its preclinical and clinical staff in california and discovery operations both in california and in brisbane queensland australia for further information please visit httpwwwprotagonistinccom logo  httpphotosprnewswirecomprnhmmlogoto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleaseswilliamdwaddillcalitheracfoelectedtoprotagonisttherapeuticsboard9htmlsource protagonist therapeutics inc read at biospacecom related news calithera biosciences inc cala reports phase i data for cb9 in patients with hematological malignancies at the th american society of hematology annual meeting biotech execs in search of human guinea pigs find eager subjects themselves calithera biosciences inc cala to present new phase  solid tumor dose expansion data of cb9 at the  aacrncieortc international conference dyslexic entrepreneur says his disability helped him build bioteam calithera biosciences inc cala presents preclinical study findings for cb9 at the  novel cancer therapeutics summit charles river  crl ceo companies that don’t grow die protagonist therapeutics initiates phase  study with oral peptide ptg revive therapeutics names a new ceo and president protagonist therapeutics to present new data for ptg and ptg at digestive disease week  taro taro ceo to return to sun pharma sunpharmans hq by the end of  please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • calithera biosciences inc • protagonist therapeutics   • biotechpharma  personnel                 waddill william d  sarasota fl  read reviews  get a bid  buildzoom × want a quote from waddill william d we recommend getting  quotes for any construction project use our free bidding system to get a quote from waddill william d   more of the best tell us about your project is this your business claim now  w bz score  license   sarasota fl waddill william d this is my business contact us bz score  write a review summary building permits  this is my business request a quote home  search  sarasota  best architects in sarasota updated jan   overview waddill william d in sarasota fl holds a landscape architect license  according to the texas license board their buildzoom score of  indicates that they are licensed or registered but we do not have additional information about themtheir license  was verified as active when we last checked if you are thinking of hiring waddill william d we recommend doublechecking their license status with the license board and using our bidding system to get competitive quotes project types offered architectural drawings and  other architecture and engi contact street address kimleyhorn and associates inc sarasota fl  edit do you work for this business unlock this free profile to update company info and see whos viewing your profile notable building permits filed by waddill william d sort by notable notable  date date  job value job value sign 9 w franklin ave los angeles ca 9  new monument sign x entry monument sign x and vehicular entry sign x valuation  permit   status reviewed by supervisor fee na permit type onsite building type na nonbldgnew 9 w franklin ave los angeles ca 9   ft ht wood fence  ft ht concrete wall and  fountains repair one new fountain valuation  permit   status reviewed by supervisor fee na permit type commercial building type na grading 9 w franklin ave los angeles ca 9  grading permit for site preparation valuation  permit   status reviewed by supervisor fee na permit type commercial building type na similar contractors see more  f mcintosh rd sarasota fl  unique pools  designs inc license  cpc9 sarasota fl  bz score k avg project  projects 9 st terrace e bradenton fl    ext  aqua designs  decor license   bradenton fl  bz score k avg project  projects  nd st north safety harbor fl 9 elite designs unlimited inc license  flc safety harbor fl  bz score  avg project  projects waddill william d reviews buildzoom hasnt received any reviews for waddill william d click here to be alerted when reviews are posted about them please write a review about waddill william d  rate this architect click stars to rate  provide a detailed review of this architect recent buildzoom projects view all custom home build restaurant buildout swimming pool project kitchen remodel bathroom remodel request a quote explore buildzoom if you are considering hiring waddill william d we recommend doublechecking their license status with the license board and using our bidding system to get competitive quotes hiring a contractor get bids from buildzooms best contractors within  mins during regular business hours by filling out this form i need help with zip code request quotes from  waddill william d  unique pools  designs inc  aqua designs  decor  elite designs unlimited inc request a quote license info verified license license statusactivestatetexastypelandscape architect buildzoom has not verified this license since april verify this licenses status for waddill william d at the texas department of licensing and regulation  buildzoom score how the buildzoom score works follow this contractor employees waddill william d owner before you hire here are some rules regulations and laws governing general contractors in texas does waddill william d carry a valid contracting license only certain types of specialty contractors eg hvac electrical need to be licensed in texas there are no licensing requirements when it comes to hiring for a construction or major remodeling project waddill william d currently holds license  landscape architect which was active when we last checked how important is contractor licensing in texas the texas department of licensing and regulation tdlr regulates hvac and electrical contractors you should verify their license status on the tdlr website before hiring general contractors and home builders are not licensed so you should do additional research before hiring one your liability risk when hiring waddill william d although it isnt a regulatory requirement you can ask your general contractor to provide evidence of workers compensation and general liability insurance prior to hiring them financial recourse when hiring waddill william d the texas department of licensing regulation does not require general contractors to carry a surety bond nor is there a state recovery fund what else should i know before hiring waddill william d there is no financial or criminal background check performed on general contractors by the tdlr the states department of public safety does maintain a publicly accessible database so you can run your own background check prior to hiring how is the buildzoom score calculated the buildzoom score is based on a number of factors including the contractors license status insurance status verified work history standing with local consumer interest groups verified reviews from other buildzoom users and selfreported feedback from the contractor why you should hire through buildzoom the information on buildzoom is made available as a public service and should not be considered advertising we collect client feedback and verify contractors permitted history with dozens of local building departments in texas which saves you time and helps minimize your risk when hiring you should get several bids before hiring a contractor the texas attorney generals office recommends getting several bids before hiring a contractor do not automatically accept the lowest bid  an abnormally low bid may indicate the contractor made a mistake and is not including the same work quoted by their competitors weve made the bid collection process extremely simple and free about buildzoom buildzoom has one simple purpose to help you find the perfect contractor for any job commercial or residential buildzoom is a database of every licensed contractor in the united states we work hard to figure out who the great contractors are and who the bad contractors are more buildzoom combines license information on  million contractors with  million building permits and over  reviews from property ownersif you are looking for a specific contractor and you can’t find them on buildzoom it’s likely that they do not have a license  please contact us and we’ll try to help finding a contractor through buildzoom the best way to use buildzoom is to let us recommend contractors for your remodeling projects homeowners who hire through buildzooms free bidding system report high rates of satisfaction and homeowners who research contractors online are twice as likely to be happy at the end of their project if you hire a contractor through buildzoom that contractor is accountable to us we can enforce standards of behavior mediate disputes and guarantee satisfaction read more about why hiring through buildzoom is so effective less press coverage buildzoom’s database now contains every licensed contractor across the us  over  million of them categorized contractor profiles are enriched using government data from state licensing boards better business bureau ratings and more… buildzoom jumped into the fray by announcing that it raised  million in a round led by formation  the y combinatorbacked startup said it will be focused on remodeling projects where the median budget is around 9… a new index compiled by buildzoom — which identifies contractors for projects — found that renovations are running  percent above their  level… × contact waddill william d we will attempt to deliver your message to waddill william d well notify you when it is delivered your name your email your phone optional your message im interested in speaking with you about a project are you available to chat today ‹ › × × how the buildzoom score works read more about the buildzoom scoring algorithm here a licensed contractor starts with  points their score will increase or decrease based on these variables positive client feedback verified license  insurance project history community participation profile page content employee info years in business contact info project photos suspended or inactive license negative client feedback limited work history browse remodeling photos if you are looking for remodeling ideas you can browse hundreds of beautiful photos of work performed by our general contractors browse building permits you can use our building permit search to see the contractors who are active in your neighborhood and the projects currently taking place get a cost estimate use our remodeling calculator to get a ballpark estimate for your project if youre ready to hire use our bidding system to get actual quotes from local contractors sorbent therapeutics appoints jay shepard and william waddill to board of directors email protected twitterlinkedin about our vision our mission our team our values our partners faq terms  conditions privacy policy board news latest board news board news by location… europe usa  canada middle east all the others board news by company type public  listed vc  pe backed privately held trust  fund  reit board news by industry… life sciences  health care financials information technology women on board submit a press release board directory company press releases public  listed global  fortune  private or vc  pe backed unicorns trust  fund newsletter contact log in register select pageabout    our vision our mission     our team     our values     our partners     faq     terms  conditions     privacy policy board news    latest board news     board news by location…        europe         usa  canada         middle east         all the others     board news by company type        public  listed         vc  pe backed         privately held         trust  fund  reit     board news by industry…        life sciences  health care         financials         information technology     women on board     submit a press release board directory    company press releases     public  listed     global      fortune      private or vc  pe backed     unicorns     trust  fund newsletter contact log in register homeboard  usa  can board privately held companies board vcpe backed companies sorbent therapeutics appoints jay shepard and william waddill to board of directors sorbent therapeutics appoints jay shepard and william waddill to board of directors june   by talentboards team comments are off board  usa  can board privately held companies board vcpe backed companies – usa ca – sorbent therapeutics inc a biopharmaceutical company developing therapies for cardiovascular and renal diseases today announced the appointment of jay shepard and william d waddill to the company’s board of directors mr shepard currently serves as an executive partner at sofinnova ventures and has more than  years of commercial and company building experience in the specialty pharmaceutical and biotechnology industry  mr waddill is the senior vice president chief financial officer of privately held calithera biosciences with more than  years of biotechnology experience focused on corporate financial matters “we are excited to have jay and will join our board  jay’s significant expertise in pharmaceutical marketing and commercialization and his success as a biotechnologyexecutive will be extremely valuable to sorbent as our lead product candidate clp advances through latestage clinical trials in heart failure” said detlef albrecht md sorbent’s president and chief executive officer “will brings tremendous firsthand knowledge of private and public fundraising financial management and the finance and governance aspects of partnerships  together their insights will support sorbent’s executive team in achieving our strategic goals” jay shepard is currently executive partner at sofinnova ventures following his role as chief executive officer of nextwave pharmaceuticals through its sale for  million to pfizer in   from  to  he was an executiveinresidence at sofinnova ventures  prior to that mr shepard was president and chief executive officer of ilypsa a nephrology therapeutics company acquired for  million by amgen in   he then served as interim president and chief executive officer at relypsa an ilypsa spinout company  prior mr shepard held senior leadership roles at telik and alza corporation now johnson  johnson  mr shepard is currently executive chairman of versartis inc and serves as a board member of bullet biotechnologies marinus pharmaceuticals durect corporation and the santa clara university entrepreneurial school  he holds a bs in business administration from the university of arizona will waddill joined calithera biosciences as senior vice president chief financial officer in april  he began his career  years ago in commercial banking and public accounting and has been in the biotechnology industry for over  years prior to joining calithera mr waddill was senior vice president chief financial officer at oncomedpharmaceuticals from  to  where he was responsible for all corporate financial matters most notably the successful completion of a 9 million initial public offering injuly  private equity financing of  million in december  and three collaborations collectively valued at  billion  prior to oncomed mr waddill was senior vice president cfo at ilypsa where he was the finance lead for the  millionacquisition by amgen in   before joining ilypsa mr waddill served as the founder and principal at square one finance a financial consulting business managing the finances of  startup biotechnology companies including eight that became public and six that were acquired  mr waddill serves on the board of the association of bioscience financial officers and was formerly the chairman of the biotechnology industry organization bio bio business solutions advisory board and finance and tax committee  he received a bs in accounting from the university of illinois chicago and certification as a public accountant inactive after working at pricewaterhousecoopers and deloitte in boston sorbent’s lead product clp is a crosslinked polyelectrolyte polymer intended to selectively bind to and remove excess water and sodium in the gi tract  clp is currently being studied in the phase b stepwise clinical trial to assess the safety tolerability and efficacy of clp therapy in addressing the signs and symptoms of fluid overload in heart failure patients  sorbent completed a phase a study with clp in  patients that demonstrated favorable effects on many of the signs and symptoms of heart failure in patients with advanced symptomatic heart failure and chronic kidney disease about sorbent therapeutics sorbent therapeutics is a private biopharmaceutical company developing therapies for patients requiring targeted cation and fluid removal from the body  the company is focused on the development of nonabsorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure endstage renal disease chronic kidney disease and hypertension  sorbent is headquartered in sunnyvale california  disclaimer  news data and statement included in this release are intended exclusively for information purposes product and brand names used in this release maybe trademarks or registered trade marks of their respective owners talentboards accepts neither liability for the consequences of the reader’s reliance nor responsibility for the adequacy or accuracy of this release no data or statement in this release should be considered a recommendation for the purchase retention or sale of the securities referred to hereinother related postsprotagonist therapeutics elects will waddill to the board of directorsdurect appoints jay shepard to its board of directorsfive prime therapeutics appoints bill ringo to the board of directorstalentboards team comments are closed latest boardroom news standard chartered announces dr ngozi okonjoiweala to its board as upcoming independent nonexecutive director july   tristar resources appoints mark wellesleywood as executive chairman july   pacific city financial appoints sang lee as new chairman of the board of directors july   medallion financial adds john everets to its board as independent director july   morgan stanley announces board member tom glocer as upcoming independent lead director july   random boardsamrestimage sensing systemsuns energyaxis bankhampshire group    talentboards inc  all rights reserved  geneva  miami  london  boston  paris  shanghai  monaco